Pregabalin for Abdominal Pain From Adhesions
Pregabalin for Abdominal Pain From Adhesions
The purpose of this study is to evaluate if pregabalin demonstrates significant reduction in
 abdominal pain from adhesions.
The study will be prospective, double-blinded and randomized. The study will run for 12
 weeks. During the first 7 weeks there will be 2 groups in the study with subjects receiving a
 placebo or the study drug. During the last 4 weeks of the study, all subjects will be offered
 the study medication, pregabalin. The primary outcome measure will be pain relief documented
 by a 2-point change on the Likert pain scale with a secondary pain measure of sleep
 interruption.
Inclusion Criteria:

 -  Must have history of prior surgery and documented adhesions during laparoscopy or open
 laparotomy within 5 years

 -  Must have undergone an evaluation to exclude other causes of abdominal pain

 -  Abdominal pain must be present for greater than three months duration

 Exclusion Criteria:

 -  Patients that are pregnant or breast feeding

 -  Prior treatment with gabapentin, pregabalin or demonstrated sensitivity to these drugs

 -  Patients who are immunocompromised

 -  Patients with significant hepatic or renal insufficiency, or any significant
 hematologic disorder

 -  History of illicit alcohol or drug abuse within one year

 -  Documented serious or unstable medical or psychological condition

 -  Malignancy within the past 5 years other than in situ squamous cell carcinoma of the
 skin